Meeting
2023 ASCO Annual Meeting
Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
Authors
Joel W. Neal
Stanford University Medical Center, Stanford, CA
Joel W. Neal , Ying Li , Ziji Yu , Robert J. Fram , Christopher Danes , Sylvie Vincent , Zofia Piotrowska
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02716116
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9082)
DOI
10.1200/JCO.2023.41.16_suppl.9082
Abstract #
9082
Poster Bd #
70
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.
First Author: Suresh S. Ramalingam
Poster
2022 ASCO Annual Meeting
Phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations.
First Author: Alexander I. Spira
Poster
2023 ASCO Breakthrough
CRISPincette, and detection of low frequency cancer mutations in ctDNA.
First Author: Jin-Soo Kim
Poster
2023 ASCO Annual Meeting
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.
First Author: Danny Nguyen